Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Classical hematology 1

Conditions

Neoplasms 2Plexosarcoma 1Gastrointestinal Stromal Tumors 1Anemia, Iron-Deficiency 1Anemia 1

Interventions

Gemcitabine 57Paclitaxel 50Cyclophosphamide 45pembrolizumab 44Carboplatin 41Bevacizumab 38Cisplatin 33Docetaxel 31Fluorouracil 30Nivolumab 29Capecitabine 29Pemetrexed 24Irinotecan 24Oxaliplatin 23Dexamethasone 23Ipilimumab 22Leucovorin 21Radiotherapy 20Sorafenib 19Doxorubicin 19Everolimus 18Cetuximab 18fludarabine 17Albumin-Bound Paclitaxel 17trametinib 15Sunitinib 15Rituximab 15Erlotinib Hydrochloride 15130-nm albumin-bound paclitaxel 15Prednisone 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Neoplasms × Iron-Dextran Complex × Clear all
NCT01145638 2015-12-03

A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)

Pharmacosmos A/S

Phase 3 Completed
350 enrolled 9 charts
Tumor-Agnostic

Neoplasms

NCT00401544 2014-01-29

Darbepoetin Alfa With or Without Intravenous (IV) Iron

Amgen

Phase 2 Completed
243 enrolled 26 charts
Classical hematology

Anemia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡